Aripiprazole-Induced Agitation After Clozapine Discontinuation: A Case Report
Dara Y. Cho Jean-Pierre Lindenmayer
J Clin Psychiatry 2009;70(1):141-143 [letter]
10.4088/JCP.08104528
© Copyright 2015 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Clozapine continues to be the gold standard for patients
with treatment-refractory schizophrenia.1 However, when patients
who have responded to clozapine need to have clozapine
treatment discontinued due to a serious adverse event, such as
glucose abnormalities, clinicians are often confronted with difficult
choices regarding a suitable substitute treatment.
We present a patient who developed acute ketoacidosis
while on clozapine treatment and who developed severe agitation
and psychotic decompensation with subsequent aripiprazole
treatment.